Status:

NOT_YET_RECRUITING

The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage

Lead Sponsor:

Assiut University

Conditions:

Systemic Lupus Erythematosus

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The SLE is heterogeneous multisystem autoimmune disease with complex pathogenesis involves multiple cellular components of the innate and adaptive immune systems, presence of autoantibodies and immune...

Eligibility Criteria

Inclusion

  • : Adult SLE Patients ( \>18 years ) who are fulfilling the 2019 ACR\\EULAR classification criteria of systemic lupus erythematosus

Exclusion

  • SLE patients \<18 years old
  • Patients with other autoimmune diseases (systemic sclerosis , sjogren syndrome, rheumatoid arthritis dermatomyositis, mixed connective tissue disease).
  • Pregnant and lactating women .
  • \-

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2028

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT07136337

Start Date

September 1 2025

End Date

January 1 2028

Last Update

August 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assiut university hospital

Asyut, Asyut Governorate, Egypt, 1111

The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage | DecenTrialz